Ge X, et al. - Researchers undertook a meta-analysis with 17 clinical trials, comprising 2,198 patients, including 644 males and 1,554 females, to define the variations in the proportions of BMPR2 (bone morphogenetic protein receptor) mutations in familial hereditary pulmonary arterial hypertension (HPAH) and idiopathic pulmonary arterial hypertension (IPAH) between males and females, as well as, they examined the association between BMPR2 mutation and pulmonary arterial hypertension (PAH) severity. The included studies were identified from electronic Cochrane Library, PubMed/MEDLINE, and EMBASE databases. A higher BMPR2 mutation rate was evident in males vs females among patients with HPAH and IPAH. Findings revealed more severe haemodynamic as well as functional parameters in IPAH and HPAH patients with BMPR2 mutations vs in those without, and younger age at diagnosis was reported in those with BMPR2 mutation. PAH patients with BMPR2 mutations vs those without had higher risk of death or transplantation. The difference was significant only in males and not in females. Overall, a greater probability of having BMPR2 mutations was noted in men among patients with HPAH and IPAH, and the presence of these mutations may predict more severe PAH indications and prognosis.